Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by M. Tan
Local Price and Clarithromycin Resistance Shape the Cost of Vonoprazan Triple Therapy for Helicobacter pylori Eradication
No abstract is available for this article. Data Availability Statement The author has nothing to report. References 1, , and , “High Potency Proton Pump Inhibitor Versus Vonoprazan in Helicobacter pylori Triple Therapy,” Helicobacter 31, no. 4 (2026): e70152, https://doi.org/10.1111/hel.70152. 2, , , , , and , “Vonoprazan-Based Versus Proton Pump Inhibitor-Based Therapy in Helicobacter pylori Eradication: An Updated Systematic Review and Meta-Analysis of Randomised Trials,” Gut 73, no.
Molecular and physiological acclimation to low light and iron scarcity in a globally abundant oceanic pelagophyte
Abstract Pelagomonas calceolata is a widely distributed marine alga and is among the most numerous eukaryotes on Earth. It is abundant in subsurface chlorophyll maximum layer (SCML) communities where iron (Fe) and light are jointly scarce. To understand the strategies behind P. calceolata’s success, we profile this organism’s physiology and gene expression as it experiences Fe/light co-limitation. We describe cellular changes under steady-state Fe limitation and short-term responses to Fe resupply.
GUIDELINE DIRECTED ANTICOAGULANT TREATMENT AND DOSING IN A CONTEMPORARY CANADIAN ATRIAL FIBRILLATION COHORT
Drought priming‐induced stress memory improves subsequent drought or heat tolerance via activation of γ‐aminobutyric acid‐regulated pathways in creeping bentgrass
Request Username Can't sign in? Forgot your username? Enter your email address below and we will send you your username If the address matches an existing account you will receive an email with instructions to retrieve your username
Reading and erasing of histone crotonyllysine mimics by the AF9 YEATS domain and SIRT2 deacylase
Under a Creative Commons license open access 1.
Advance Care Planning With Black Women with Breast Cancer: A Community Health Worker Model.
Cancer Control : Journal of the Moffitt Cancer Center, Apr 2023 This is a preview of a remote PDF: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020146/pdf/ M. Tan, D. Villamar, C. Huard, L. Nicholson, H. Medina, P. Moreno. , Cancer Control : Journal of the Moffitt Cancer Center, pp. 10732748231162479, DOI: 10.1177/10732748231162479
480 Does Sex-Specific High-Sensitivity Troponin T Cut-Off Values Alter Clinical Outcomes in Chest Pain Presentations to the Emergency Department?
487 Evaluating for Discrepancies in Post ST–Elevation Myocardial Infarction Care in Women Compared to Men: Defining the Aetiology of Implicit Bias- A Single Centre Study
EVIDENCE OF OVERCOMING TREATMENT INERTIA IN PATIENTS WITH CARDIOVASCULAR DISEASE OR FH
Expand allCollapse all Background Lowering of LDL-C is recommended in patients with CVD or familial hypercholesterolemia (FH). Canadian guidelines recommend additional therapy on top of statin in those patients who do not achieve recommended LDL-C level. GOAL is an investigator initiated study to ascertain the use of second and third line therapy and its impact on LDL-C in a real world setting. Methods and Results GOAL has completed enrolment and follow up is being completed.
GUIDELINES ORIENTED APPROACH TO LIPID LOWERING (GOAL) MEDICAL PRACTICE ACTIVITY (MPA) TO ACHIEVE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) TARGETS
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. FiguresLowering of LDL-C < at least 2.0 mmol/L is recommended to decrease risk for CV events in high risk patients. Despite widespread use of statins, it is estimated that 40 - 50% of Canadian patients with known CVD do not achieve LDL-C target.
CONTEMPORARY ANTIPLATELET THERAPY IN MODERATE TO HIGH-RISK PATIENTS WITH NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION: INSIGHTS FROM THE CANADIAN ACS REFLECTIVE II STUDY
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. FiguresAmong patients with myocardial infarction (MI), higher potency ADP receptor inhibitors (ADPri) (e.g. ticagrelor) are associated with greater reduction in events compared with clopidogrel.
CONTEMPORARY USE OF ORAL ANTITHROMBOTIC THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CONNECT AF+PCI STUDY
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. FiguresPatients with non-valvular atrial fibrillation (NVAF) undergoing percutaneous coronary intervention (PCI) have traditionally been treated with “triple therapy” including aspirin, P2Y12 receptor inhibitor and oral anticoagulant (OAC).
Reducing Risk of Esophageal Cancer in Barrett's Esophagus
Background: Proton pump inhibitors (PPIs) and histamine–2 receptor antagonists (H2RAs) may reduce the risk of oesophageal adenocarcinoma (OAC) in Barrett's oesophagus; however, current epidemiologic studies are inconclusive. Aim: To evaluate the independent effects of PPIs and H2RAs on risk of OAC in patients with Barrett's oesophagus. Methods: We conducted a nested case–control study of male veterans diagnosed with Barrett's oesophagus.
Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case‐control study in US male veterans
Proton pump inhibitors (PPIs) and histamine‐2 receptor antagonists (H2RAs) may reduce the risk of oesophageal adenocarcinoma (OAC) in Barrett's oesophagus; however, current epidemiologic studies are inconclusive. To evaluate the independent effects of PPIs and H2RAs on risk of OAC in patients with Barrett's oesophagus. We conducted a nested case‐control study of male veterans diagnosed with Barrett's oesophagus.
GUIDELINES ORIENTED APPROACH TO LIPID (GOAL) MEDICAL PRACTICE ACTIVITY (MPA) TO ACHIEVE LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) TARGETS
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Lowering of LDL-C < 2.0 mmol/L is a key recommended step in decreasing the risk for cardiovascular (CV) events in high risk patients. Despite widespread use of statin therapy as first line therapy, it is estimated that 40 – 50% of Canadian patients with known CVD do not achieve LDL-C target.
Cutaneous protothecosis on the bilateral wrists of a food handler
Cutaneous protothecosis is caused by the achlorophyllic algae Prototheca, typically presenting as a localized plaque in immunocompetent individuals. We report a patient with bilateral erythematous plaques and pustules on her forearms, which had initially been treated with steroids for presumed eczema. Histology showed spherical spore-like bodies with internal morula-like septation, which were positive for periodic-acid–Schiff (PAS) staining, consistent with cutaneous protothecosis.
516P Utility of colonoscopy in diagnosing familial adenomatous polyposis (FAP) among patients (pts) with desmoid tumors (DT)
516P Utility of colonoscopy in diagnosing familial adenomatous polyposis (FAP) among patients (pts) with desmoid tumors (DT) Z. Zhang1, M. Teo2, K.C. Soo2, M.H. Tan2, A.Y-F. Chung2, W.L. Goh1, S. Sathiyamoorthy3, K. Sittampalam3, J. Teh4, F. Chin4, S-T. Li1, J. Ngeow5, M. Farid1 and R.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with M.
Contact M., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack